Drug Trial Radar · NCT00400153
Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Jun 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,480
Actual
Start
Nov 2006
Primary completion
Apr 2008
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 16, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat® inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat® inhaler (20 mcg), and COMBIVENT® MDI administered q.i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat® to COMBIVENT® MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat® to Atrovent Respimat® monotherapy in FEV1 AUC from 4 to 6 hours will be analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
Atrovent Respimat (20 mcg)Drug
COMBIVENT MDI (36/206 mcg)Drug
Combivent Respimat (20 mcg/100 mcg)Drug
Placebo via corresponding inhaler for blinding purposesDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- FEV1 AUC0-6 at Day 85Time frame: Before drug administration to 6 hours after drug administration on Day 85
- FEV1 AUC0-4 at Day 85Time frame: Before drug administration to 4 hours after drug administration on Day 85
- FEV1 AUC4-6 at Day 85Time frame: Between 4 hours and 6 hours after drug administration on Day 85
Locations
180 sites in 13 countries. Site status is shown where the registry gives one.
1012.56.01006 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1012.56.01051 Boehringer Ingelheim Investigational Site
Jasper, Alabama
1012.56.01071 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1012.56.01039 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
1012.56.01012 Boehringer Ingelheim Investigational Site
Lakewood, California
1012.56.01029 Boehringer Ingelheim Investigational Site
Los Angeles, California
1012.56.01043 Boehringer Ingelheim Investigational Site
Palo Alto, California
1012.56.01089 Boehringer Ingelheim Investigational Site
Rancho Mirage, California
1012.56.01021 Boehringer Ingelheim Investigational Site
Riverside, California
1012.56.01033 Boehringer Ingelheim Investigational Site
San Jose, California
1012.56.01020 Boehringer Ingelheim Investigational Site
Sepulveda, California
1012.56.01045 Boehringer Ingelheim Investigational Site
Torrence, California
1012.56.01040 Boehringer Ingelheim Investigational Site
Denver, Colorado
1012.56.01050 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado
1012.56.01018 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
1012.56.01062 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado
1012.56.01036 Boehringer Ingelheim Investigational Site
Hartford, Connecticut
1012.56.01025 Boehringer Ingelheim Investigational Site
Stamford, Connecticut
1012.56.01088 Boehringer Ingelheim Investigational Site
Waterbury, Connecticut
1012.56.01007 Boehringer Ingelheim Investigational Site
Bay Pines, Florida
1012.56.01058 Boehringer Ingelheim Investigational Site
Brandon, Florida
1012.56.01010 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1012.56.01065 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1012.56.01024 Boehringer Ingelheim Investigational Site
DeLand, Florida
1012.56.01001 Boehringer Ingelheim Investigational Site
Melbourne, Florida
1012.56.01023 Boehringer Ingelheim Investigational Site
Panama City, Florida
1012.56.01052 Boehringer Ingelheim Investigational Site
Pensecola, Florida
1012.56.01048 Boehringer Ingelheim Investigational Site
Tampa, Florida
1012.56.01093 Boehringer Ingelheim Investigational Site
Winter Park, Florida
1012.56.01077 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1012.56.01083 Boehringer Ingelheim Investigational Site
Decatur, Georgia
1012.56.01008 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho
1012.56.01019 Boehringer Ingelheim Investigational Site
Olathe, Kansas
1012.56.01056 Boehringer Ingelheim Investigational Site
Wichita, Kansas
1012.56.01066 Boehringer Ingelheim Investigational Site
Bowling Green, Kentucky
1012.56.01090 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
1012.56.01054 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana
1012.56.01072 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana
1012.56.01070 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
1012.56.01035 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.